Correction: Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM)
Breast Cancer. 2024 Sep 20.
doi: 10.1007/s12282-024-01632-z.
Online ahead of print.